Overview

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

Status:
Active, not recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, extension study to evaluate the long-term safety, tolerability, and efficacy of treatment with AG-348 in participants who were previously enrolled in Study AG348-C-006 or Study AG348-C-007.
Phase:
Phase 3
Details
Lead Sponsor:
Agios Pharmaceuticals, Inc.